**What is already known**

Serial high-sensitivity cardiac troponin measurements are essential to diagnose acute myocardial infarction. Recent studies have investigated the role of copeptin, the C-terminal part of arginine vasopressin, for the multi-marker strategy. However, high-sensitivity cardiac troponin assays were not used, and only additional diagnostic performance of copeptin was examined in most studies.

**What is new in the current study**

The combined measurement of copeptin and high-sensitivity cardiac troponins showed 100% (87.7% to 100%) sensitivity and 100% (97.7% to 100%) negative predictive value for acute myocardial infarction. Moreover, the negative predictive value of the multi-marker strategy was not inferior to that of serial high-sensitivity cardiac troponin assays.

INTRODUCTION
============

Acute myocardial infarction (AMI) is a leading cause of death worldwide, and chest pain is one of the most common complaints in the emergency department (ED) \[[@b1-ceem-19-013]\]. Although ST-elevation myocardial infarction (STEMI) can be identified using electrocardiography (ECG), the diagnosis of non-ST-elevation myocardial infarction (NSTEMI) is challenging \[[@b2-ceem-19-013]\]. Cardiac troponins (cTns) are essential for NSTEMI diagnosis because of their high sensitivity and specificity. However, even in the era of high-sensitivity cardiac troponins (hs-cTns), serial measurements are mandatory because of the "troponin-blind interval \[[@b2-ceem-19-013]\]."

Arginine vasopressin (AVP) plays an important role in maintaining hemodynamic stability through its antidiuretic and vasoconstriction effects in stressful conditions including AMI \[[@b3-ceem-19-013]\]. However, the utility of AVP as a biomarker is limited because AVP is a small 9-amino acid peptide, which is mostly bound to platelets, and its plasma half-life is only 24 minutes \[[@b4-ceem-19-013]\]. By contrast, copeptin is a 39-amino acid peptide synthesized in the hypothalamus as the C-terminal part of the AVP prohormone. It is released in equimolar amounts with AVP and remains stable in plasma \[[@b5-ceem-19-013]\]. This makes copeptin a surrogate marker for AVP in clinical conditions with high endogenous stress such as sepsis and AMI \[[@b6-ceem-19-013]\].

Many studies have investigated the multi-marker strategy using cTn and copeptin at admission for the rapid rule-out of NSTEMI \[[@b7-ceem-19-013]-[@b13-ceem-19-013]\]. However, they used conventional cTn assays or evaluated the additive diagnostic performance of copeptin to a single cTn assay \[[@b7-ceem-19-013]-[@b13-ceem-19-013]\]. Furthermore, the additive diagnostic performance does not result in sufficient sensitivity to safely rule out NSTEMI in some studies \[[@b8-ceem-19-013],[@b9-ceem-19-013],[@b12-ceem-19-013]\].

Thus, we aimed to compare the multi-marker strategy (copeptin and hs-cTn) at admission with serial hs-cTn measurements to rule out NSTEMI in ED patients with chest pain. We hypothesized that the negative predictive value (NPV) of the multi-marker strategy for NSTEMI is not inferior to that of serial hs-cTn measurements.

METHODS
=======

Study design
------------

This prospective observational study was performed in a single tertiary ED with an annual census of approximately 70,000 patients from January 2018 to August 2018. The study protocol was approved by the institutional review board (1709-126-890), and written informed consent was obtained from all participants.

Study setting and population
----------------------------

Patients who presented to the ED with complaints of chest pain were prospectively screened by a single researcher from 8:00 to 17:00 during weekdays. Patients were enrolled in the study if they did not fulfill the following exclusion criteria: age ≤18 years, symptom onset to arrival time ≥12 hours, STEMI on ECG, and refusal to participate.

Study protocol
--------------

The standardized protocol for patients with chest pain included history taking, physical examinations, ECG, serial high-sensitivity cardiac troponin I (hs-cTnI) measurements (0 and 2 hours), chest X-ray, and other laboratory examinations \[[@b14-ceem-19-013]\]. If STEMI was suspected on ECG, then the interventional cardiology team was notified for immediate coronary angiography (CAG) and percutaneous coronary intervention. Cardiology consultation was performed for further evaluation and management when hs-cTnI was elevated. When serial hs-cTnI was within the normal limit, thrombolysis in myocardial infarction (TIMI) risk score was evaluated. Patients with a TIMI score of 2 or more require additional testing such as coronary computed tomography angiography to evaluate for coronary lesions. Patients with a TIMI score of 0 or 1 were considered as low risk and thus could be discharged. The final discharge decision was at the discretion of the attending physician. An out-patient follow-up was recommended for all discharged patients.

Measurements of clinical data
-----------------------------

The following patient information and clinical findings were obtained: age, sex, family history of coronary artery disease, hypertension, diabetes mellitus, hyperlipidemia, smoking, known coronary artery disease, aspirin use in the past 7 days, severe angina (≤2 episodes in 24 hours), ST changes ≥0.5 mm on ECG, chest pain characterization (onset, location, duration, and radiation), TIMI risk scores, biomarkers (copeptin at 0 hour and hs-cTnI at 0 and 2 hours), additional diagnostic testing (coronary computed tomography angiography, treadmill test, cardiac scintigraphy, CAG, and percutaneous coronary intervention), ED disposition, and hospitalization outcome.

Measurement of biomarkers
-------------------------

Blood was drawn at admission (0 hour) and after 2 hours to measure hs-cTnI. Samples in serum separator tubes were transferred to the central laboratory and centrifuged, and the serum was then separated. ARCHITECT STAT High Sensitive Troponin-I assay (Abbott Laboratories, Abbott Park, IL, USA) was used for the analysis. The hs-cTnI assay has a 99th percentile concentration of 26.2 ng/ L with a corresponding coefficient of variation of 4% and a limit of detection of 1.2 ng/L \[[@b15-ceem-19-013]\].

Copeptin was measured from the same blood sample drawn for hs-cTnI measurement after written informed consent was obtained. Thermo Scientific B·R·A·H·M·S Copeptin proAVP KRYPTOR assay (B.R.A.H.M.S. GmbH, Hennigsdorf/Berlin, Germany) was used. The assay has a 95th percentile concentration of 9.8 pmol/L with a corresponding intra-assay coefficient of variation of \<8% and a limit of detection of 0.69 pmol/L.

Laboratory technicians were blinded to patient data, and test results were reported to the treating physicians. Measured biomarkers were considered abnormal when hs-cTnI was \>26.2 ng/ L and when copeptin was \>10 pmol/L \[[@b16-ceem-19-013]\].

Outcome measures
----------------

NSTEMI was defined as a typical rise and fall of hs-cTnI (a peak concentration of hs-cTnI had a relative change over 50% if hscTnI at 0 and 2 hours were abnormal, but less than 100 ng/L; or a peak concentration of hs-cTnI had a relative change over 20% if hs-cTnI at 0 and 2 hours were abnormal and higher than 100 ng/ L) with any of the following: typical ischemic chest pain, new pathologic Q wave on ECG, symptomatic ST-segment depression on ECG, and coronary stenosis on CAG \[[@b17-ceem-19-013]\].

Sample size calculation and hypothesis testing
----------------------------------------------

The study hypothesis was that the multi-marker strategy using copeptin and hs-cTnI at 0 hour was non-inferior to serial hs-cTnI measurements (0 and 2 hours) in terms of NPV. The prevalence of NSTEMI was estimated at 10%. The diagnostic performance of both serial hs-cTnI measurements and the multi-marker strategy was estimated at a sensitivity of 87% and a specificity of 92% \[[@b18-ceem-19-013],[@b19-ceem-19-013]\]. Based on the prevalence, sensitivity, and specificity, NPV was calculated as 98.45%. With the estimated NPVs of both tests and the non-inferiority margin of 4%, a sample size of 235 subjects achieves 90% power at a 2.5% significance level when the probability of NSTEMI patients who were diagnosed as negative in both tests is 0% and the probability of non-NSTEMI patients who were diagnosed as negative in both tests is 82.7%, which is the maximum possible value given the prevalence, sensitivity, and specificity. Accounting for a non-evaluable rate of 10%, a total of 262 enrolled patients were required for the study. This sample size was derived based on the multinomial-based Wald statistic, which is a test statistic for the comparison of predictive values within a paired design that follows a chi-square distribution with one degree of freedom asymptotically under the null hypothesis \[[@b20-ceem-19-013]\].

The sample size calculation and analysis of a non-inferiority test for the difference between two NPVs were advised by the Medical Research Collaborating Center (2017-0114).

General statistics
------------------

Categorical variables were presented as numbers with percentages, and continuous variables as median with interquartile range. A chi-square test or Fisher exact test was used to compare the categorical variables, as appropriate. The Wilcoxon rank-sum test was performed to compare the differences in continuous variables between the two groups. The diagnostic performance of biomarkers at each cutoff was evaluated in terms of sensitivity, specificity, positive predictive value (PPV), NPV, and area under the receiver operating characteristic curve (AUROC). Sensitivity, specificity, PPV, and NPV were presented as percentages with 95% confidence intervals (CIs). A P-value less than 0.05 was considered statistically significant. Stata ver. 13.1 (StataCorp., College Station, TX, USA) was used for statistical analysis.

RESULTS
=======

Population and baseline characteristics
---------------------------------------

A total of 316 patients with chest pain were screened during the study period. With the exclusion of 46 patients who met the exclusion criteria, 270 patients provided informed consent. After excluding seven patients who violated the protocol, withdrew consent, and had no available copeptin test, 263 patients were finally included in the analysis ([Fig. 1](#f1-ceem-19-013){ref-type="fig"}).

NSTEMI was diagnosed in 28 (10.7%) patients. Patients with NSTEMI visited the ED earlier and had ischemic ECG changes more frequently ([Table 1](#t1-ceem-19-013){ref-type="table"}). Copeptin and hs-cTnI were significantly higher in patients with NSTEMI. CAG was performed in all patients with NSTEMI and 82 (34.9%) patients without NSTEMI.

Outcomes
--------

The NPVs of copeptin and hs-cTnI and serial hs-cTnI measurements for NSTEMI were 100% (97.7% to 100%) and 100% (98.2% to 100%), respectively ([Table 2](#t2-ceem-19-013){ref-type="table"}). With both NPVs of 100%, it was not possible to calculate the multinomial-based Wald statistic. Therefore, we assumed two hypothetical situations. If we assumed that the multi-marker strategy missed one NSTEMI patient, the NPV of the multi-marker strategy was 99.4% (160/161, 95% CI, 96.6% to 100%). The difference between the NPVs of the multi-marker strategy and serial hs-cTnI measurements was 0.62% (95% CI, -1.83% to 0.59%), resulting in a P-value of \<0.001. If we assumed that one of the true negative patients had NSTEMI, the NPV of the multi-marker strategy was 99.4% (159/160; 95% CI, 96.6% to 100%). The difference between the NPVs of the multi-marker strategy and serial hs-cTnI measurements was 0.63% (95% CI, -1.85% to 0.60%), resulting in a P-value of \<0.001. In both situations, the null hypothesis that the NPV of the multi-marker strategy was inferior to that of serial hs-cTnI measurements was rejected. Thus, the NPV of copeptin and hs-cTnI was not inferior to that of serial hs-cTnI measurements.

The diagnostic performance of biomarkers is described in [Table 2](#t2-ceem-19-013){ref-type="table"}. The sensitivity and NPV of copeptin alone were 46.4% (95% CI, 27.5% to 66.1%) and 92.2% (95% CI, 87.4% to 95.6%), respectively. The AUROC of the multi-marker strategy was 0.840 (95% CI, 0.811 to 0.870), which was significantly smaller than that of serial hs-cTnI measurements (0.928; 95% CI, 0.905 to 0.950) (P\<0.001).

[Fig. 2](#f2-ceem-19-013){ref-type="fig"} shows the receiver operating characteristic curve of biomarkers. The AUROC of copeptin at 0 hour (0.697; 95% CI, 0.607 to 0.786) was significantly smaller than those of hs-cTnI at 0 hour (0.952; 95% CI, 0.909 to 0.995; P\<0.001) and 2 hours (0.977; 95% CI, 0.962 to 0.993; P\<0.001).

DISCUSSION
==========

We compared the rapid rule-out performance between the multi-marker strategy using copeptin and hs-cTnI at admission and serial hs-cTnI measurements (0 and 2 hours) for NSTEMI in ED patients with chest pain. The multi-marker strategy demonstrated 100% sensitivity and 100% NPV. The NPV of the multi-marker strategy was not inferior to that of serial hs-cTnI measurements for NSTEMI diagnosis.

As mentioned in the Introduction section, many studies have investigated this multi-marker strategy for the rapid rule-out of NSTEMI \[[@b7-ceem-19-013]-[@b13-ceem-19-013]\]. Because copeptin rapidly rises after endogenous stress, such as AMI \[[@b21-ceem-19-013]\], the addition of copeptin to conventional cardiac troponin assays has increased the sensitivity for the diagnosis of AMI \[[@b7-ceem-19-013]-[@b10-ceem-19-013],[@b12-ceem-19-013]\]. However, this additive diagnostic ability should be reevaluated in the era of high-sensitivity cardiac troponin assays. Furthermore, the multi-marker strategy using copeptin and hscTn measurement should be compared with serial hs-cTn measurements.

A study reported that the combined use of copeptin and cardiac troponin I is not inferior to serial cardiac troponin I measurement in ruling out NSTEMI \[[@b22-ceem-19-013]\]. However, this study used mediumsensitivity troponin assays. Another study investigated the single combined testing of troponin and copeptin to rule out AMI, and the proportion of major adverse cardiac events is not inferior in the copeptin group to that in the standard group \[[@b16-ceem-19-013]\]. The primary outcome of interest of this study was the major adverse cardiac events during the 30-day follow-up period. A recent study was the first to compare the dual marker strategy using copeptin and high-sensitivity cardiac troponin T with other guideline-recommended fast AMI rule-out protocols and found that the dual marker strategy can be an alternative to the serial high-sensitivity cardiac troponin T-based algorithm \[[@b23-ceem-19-013]\].

We have implemented the standardized diagnostic protocol using a 2-hour hs-cTnI measurement with TIMI score in our institution several years ago \[[@b14-ceem-19-013]\]. Therefore, we wanted to compare the multi-marker strategy using copeptin and hs-cTnI at admission with the standard protocol. The advantage of using the multi-marker strategy is that rapid decision-making can reduce the length of stay of patients with chest pain in the ED. A previous study reported that the combined testing of copeptin and troponin could significantly reduce the length of stay by 3 hours without increasing the likelihood of major adverse cardiac events \[[@b16-ceem-19-013]\]. In this study, we could not compare the length of stay since copeptin and serial troponin tests were performed in all patients. However, the median reported time of hs-cTnI at 2 hours was 97 minutes longer than that of the initial sample (P\<0.001, Wilcoxon signed-rank test). According to the multi-marker strategy, 60.8% (160/263) of patients had negative results in this study. Among them, 92 patients (35.0%) had a TIMI score of less than 2 and could be safely discharged from the single sampling strategy. Earlier decision-making using copeptin may lessen unnecessary stay and thus can reserve medical resources such as beds and medical personnel for more severely ill patients, especially in the overcrowded ED.

In order to achieve such an advantage, the safety of the multi-marker strategy should be investigated thoroughly. Although the multi-marker strategy demonstrated excellent sensitivity and NPV, copeptin alone did not show enough discriminatory ability compared with hs-cTnI ([Fig. 2](#f2-ceem-19-013){ref-type="fig"}). Because copeptin is not specific to cardiac injury, the specificity and PPV were lower than those of hs-cTnI. As a result, the copeptin level was increased in 58 patients without NSTEMI. [Supplementary Table 1](#SD1-ceem-19-013){ref-type="supplementary-material"} describes the alternative diagnoses in these patients. The copeptin level was elevated in chronic kidney disease, heart failure, unstable angina, atrial fibrillation with rapid ventricular response, pneumonia, paroxysmal supraventricular tachycardia, and pulmonary embolism. In 15 patients (25.9%), there was no obvious cause of elevated copeptin. Moreover, copeptin has inverse release kinetics compared with cTn, and the sensitivity and NPV decrease when the symptom-to-arrival time is delayed \[[@b24-ceem-19-013]\]. In our study, the copeptin level was significantly higher in patients with NSTEMI when the symptom-to-arrival time was less than 180 minutes (P\<0.001). However, the copeptin level did not differ between patients with and those without NSTEMI when the symptom-to-arrival time exceeded 180 minutes (P=0.528) ([Supplementary Fig. 1](#SD1-ceem-19-013){ref-type="supplementary-material"}). As a result, copeptin missed 15 patients with NSTEMI. By contrast, hscTnI missed only one patient with NSTEMI, and this patient had an elevated copeptin level. Taken together, the combined testing of copeptin and hs-cTnI demonstrated 100% sensitivity and NPV for NSTEMI. Overall, the diagnostic value of the multi-marker strategy using copeptin and hs-cTnI for NSTEMI was primarily due to hs-cTnI.

This study has several additional limitations that need to be considered. First, this was a single-center observational study with a limited number of patients. We calculated the sample size based on a non-inferiority margin of 4% in NPV. A larger sample size from multiple institutions is required to test the narrower margin and evaluate generalizability. Second, the diagnostic performance of biomarkers was not tested according to clinical risk scores, such as the TIMI score, because of the modest number of patients.

In conclusion, the multi-marker strategy using copeptin and hs-cTnI measurement was not inferior to serial hs-cTnI measurements in terms of NPV for NSTEMI diagnosis. Both the sensitivity and NPV of the multi-marker strategy were 100%. However, the diagnostic performance of copeptin alone for NSTEMI was limited, especially in patients with delayed presentation. The specificity and PPV of the multi-marker strategy were lower than that of serial hs-cTnI. In the application of the multi-marker strategy using copeptin and hs-cTnI, these limitations should be considered.
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======================

Supplementary Table 1 and Supplementary Fig. 1 are available from: <https://doi.org/10.15441/ceem.19.013>.

![Flowchart of patient enrollment.](ceem-19-013f1){#f1-ceem-19-013}
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###### 

Characteristics of the study population

  Characteristics                                                  All patients (n = 263)   NSTEMI (n = 28)      No NSTEMI (n = 235)   P-value
  ---------------------------------------------------------------- ------------------------ -------------------- --------------------- -----------------------------------------------------
  Baseline characteristics                                                                                                             
   Age (yr)                                                        66 (57--75)              68 (59--76.5)        66 (57--75)           0.383
   Sex, male                                                       152 (57.8)               21 (75.0)            131 (55.7)            0.051
  Symptom-to-arrival time (min)                                    124 (48--269)            70 (27--136)         148 (50--280)         0.025
   \< 3 hr                                                         153 (58.2)               22 (78.6)            131 (55.7)            0.021
  Past medical history                                                                                                                 
   Hypertension                                                    127 (48.3)               14 (50.0)            113 (48.1)            0.848
   Diabetes mellitus                                               63 (24.0)                12 (42.9)            51 (21.7)             0.013
   Hyperlipidemia                                                  89 (33.8)                9 (32.1)             80 (34.0)             0.841
   Family history                                                  44 (16.7)                3 (10.7)             41 (17.5)             0.591^[a)](#tfn1-ceem-19-013){ref-type="table-fn"}^
   Smoker                                                          39 (14.8)                7 (25.0)             32 (13.6)             0.154^[a)](#tfn1-ceem-19-013){ref-type="table-fn"}^
   Known CAD                                                       79 (30.0)                6 (21.4)             73 (31.1)             0.293
  ASA use in past 7 days                                           90 (34.2)                9 (32.1)             81 (34.5)             0.806
  Ischemic ECG change                                              33 (12.6)                9 (32.1)             24 (10.2)             0.001
  TIMI risk scores^[b)](#tfn2-ceem-19-013){ref-type="table-fn"}^   1 (0--2)                 1.5 (1--3)           1 (0--2)              0.146
  Biomarkers                                                                                                                           
   Copeptin 0 hr (pmol/L)                                          5.01 (2.71--10.37)       8.92 (5.20--23.19)   4.59 (2.62--9.97)     \< 0.001
    \> 10 pmol/L                                                   71 (27.0)                13 (46.4)            58 (24.7)             0.014
   hs-TnI 0 hr (ng/L)                                              1 (1--20)                525 (105--3,905)     1 (1--1)              \< 0.001
    \> 26.2 ng/L                                                   59 (22.4)                27 (96.4)            32 (13.6)             \< 0.001
   hs-TnI 2 hr (ng/L)                                              1 (1--20)                905 (185--5,680)     1 (1--1)              \< 0.001
    \> 26.2 ng/L                                                   62 (23.6)                28 (100)             34 (14.5)             \< 0.001
   hs-TnI peak (ng/L)                                              1 (1-60)                 6815 (560-29,710)    1 (1-20)              \< 0.001
  Additional testing                                                                                                                   
   Coronary CT angiography                                         86 (32.7)                2 (7.1)              84 (35.7)             0.001^[a)](#tfn1-ceem-19-013){ref-type="table-fn"}^
   Treadmill test                                                  5 (1.9)                  0 (0)                5 (2.1)               NA
   Cardiac scintigraphy                                            7 (2.7)                  0 (0)                7 (3.0)               NA
   Coronary angiography                                            110 (41.8)               28 (100)             82 (34.9)             \< 0.001
   No testing                                                      74 (28.1)                0 (0)                74 (31.5)             NA
   PCI                                                             54 (20.5)                23 (82.1)            31 (13.2)             \< 0.001

Values are presented as median (interquartile range) or number (%).

NSTEMI, non-ST-elevation myocardial infarction; CAD, coronary artery disease; ASA, aspirin; ECG, electrocardiogram; TIMI, thrombolysis in myocardial infarction; hs-TnI, high-sensitivity troponin I; CT, computed tomography; NA, not applicable; PCI, percutaneous coronary intervention.

Fisher exact test was used for the comparison.

Positive cardiac marker was not included to calculate the TIMI score.

###### 

Performances of copeptin, hs-TnI, and combination of biomarkers for the diagnosis of non-ST-elevation myocardial infarction

  Performances                Copeptin (0 hr)        hs-TnI (0 hr)          hs-TnI (2 hr)          Copeptin and hs-TnI (0 hr)   hs-TnI (0 and 2 hr)
  --------------------------- ---------------------- ---------------------- ---------------------- ---------------------------- ----------------------
  True positive               13                     27                     28                     28                           28
  False positive              58                     32                     34                     75                           34
  True negative               177                    203                    201                    160                          201
  False negative              15                     1                      0                      0                            0
  Sensitivity                 46.4 (27.5--66.1)      96.4 (81.7--99.9)      100 (87.7--100)        100 (87.7--100)              100 (87.7--100)
  Specificity                 75.3 (69.3--80.7)      86.4 (81.3--90.5)      85.5 (80.4--89.8)      68.1 (61.7--74.0)            85.5 (80.4--89.8)
  Positive predictive value   18.3 (10.1--29.3)      45.8 (32.7--59.2)      45.2 (32.5--58.3)      27.2 (18.9--36.8)            45.2 (32.5--58.3)
  Negative predictive value   92.2 (87.4--95.6)      99.5 (97.3--100)       100 (98.2--100)        100 (97.7--100)              100 (98.2--100)
  AUROC                       0.609 (0.511--0.707)   0.914 (0.873--0.955)   0.928 (0.905--0.950)   0.840 (0.811--0.870)         0.928 (0.905--0.950)

Values are presented with 95% confidence intervals. Cutoff values were 10 pmol/L and 26.2 ng/L for copeptin and hs-TnI, respectively.

hs-TnI, high-sensitivity troponin I; AUROC, area under the receiver operating characteristic curve.
